Mr. Clifford Stocks is a Co-Founder of OncoResponse and serves as its Chief Executive Officer & Board Member. He also is an Angel Investor. He is a Board Member at Cardiac Insight. He served as Chief Executive Officer and Board Member at Theraclone Sciences. He served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in Q2 2011. Mr. Stocks brings more than two decades of experience in the biotech industry, including 15 years at ICOS Corporation where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing and deal-making. He played an instrumental role on the leadership team that developed and launched Cialis® and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks's early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago. He received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business and a Bachelor of Science degree in biology from the University of Utah.